MEDIAN Technologies Announces €422K Phase II Project Award
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging services in a new phase II clinical trial. The clinical trial is sponsored by a Top 20 pharmaceutical company and is for a highly aggressive cutaneous cancer type. The anticipated amount for the project is $ 582K equivalent to €422K for MEDIAN.
“This is an important new project awarded through our collaboration with our strategic CRO partner. In parallel, we already have several ongoing clinical studies with this pharmaceutical sponsor. This new study award demonstrates the trust they have in our company” emphasized Nicolas Dano, Director of Business Development, Europe and Asia. “With the award of this new phase II study for a specific type of cutaneous cancer, we continue to expand the range of cancer indications we cover and for which we provide highly differentiated image management and interpretation services”, he added
Within the framework of the study, imaging data will be acquired from approximately 50 clinical sites worldwide, with a start date forecasted in Q2, 2014. MEDIAN will provide the whole set of imaging services including Independent Central Review (ICR) services. ICR services will be performed by radiologists using MEDIAN’s Lesion Management Solutions (LMS) software. LMS is a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials. MEDIAN LMS provide sponsors with very accurate and reliable imaging data.
[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”